As of Mar 24
| +0.18 / +0.59%|
The 2 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 29.50, with a high estimate of 32.00 and a low estimate of 27.00. The median estimate represents a -4.22% decrease from the last price of 30.80.
The current consensus among 3 polled investment analysts is to Hold stock in Enanta Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.